Oncology Research and Treatment

Scope & Guideline

Innovating solutions for tomorrow's cancer challenges.

Introduction

Explore the comprehensive scope of Oncology Research and Treatment through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Oncology Research and Treatment in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN2296-5270
PublisherKARGER
Support Open AccessNo
CountrySwitzerland
TypeJournal
Convergefrom 1978 to 1997, from 2013 to 2024
AbbreviationONCOL RES TREAT / Oncol. Res. Treat.
Frequency10 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND

Aims and Scopes

The journal 'Oncology Research and Treatment' focuses on advancing knowledge in the field of oncology through comprehensive research articles, reviews, and clinical studies. It aims to provide insights into cancer biology, treatment methodologies, and patient care, thereby facilitating improved outcomes for cancer patients.
  1. Clinical Trials and Treatment Outcomes:
    The journal frequently publishes studies on clinical trials, exploring the efficacy and safety of new treatments, including immunotherapies, targeted therapies, and combination regimens.
  2. Molecular and Genetic Research:
    Research on the molecular and genetic underpinnings of cancer is a core focus, with articles discussing biomarkers, genetic mutations, and their implications for personalized medicine.
  3. Patient-Centered Care and Quality of Life:
    The journal emphasizes research on patient quality of life, psychosocial aspects of cancer care, and the integration of supportive therapies alongside traditional cancer treatments.
  4. Innovative Therapeutic Strategies:
    It covers innovative approaches in cancer therapy, including the development of new drugs, treatment protocols, and the use of advanced technologies like CAR-T cell therapy and gene editing.
  5. Epidemiological Studies:
    Epidemiological research addressing cancer prevalence, risk factors, and outcomes across diverse populations is regularly featured, providing valuable insights into public health aspects of oncology.
The journal has seen a rise in certain trending themes that reflect the evolving landscape of oncology research and treatment. These emerging scopes highlight areas of growing interest and innovation.
  1. Immunotherapy and Combination Treatments:
    There is an increasing emphasis on immunotherapy, particularly in combination with other treatment modalities, showcasing the potential for enhanced efficacy in cancer management.
  2. Personalized Medicine and Genomic Profiling:
    Research in personalized medicine, including genomic profiling to guide treatment decisions, is on the rise, reflecting a trend towards individualized patient care.
  3. Real-World Evidence and Patient-Reported Outcomes:
    Studies focusing on real-world evidence and patient-reported outcomes are gaining traction, emphasizing the importance of understanding treatment impacts from the patient's perspective.
  4. Digital Health and Telemedicine in Oncology:
    The incorporation of digital health tools and telemedicine for patient monitoring and care delivery has seen significant growth, especially in the context of the COVID-19 pandemic.
  5. Advancements in CAR-T Cell Therapy and Other Cell-Based Therapies:
    There is a marked increase in research related to CAR-T cell therapies and other innovative cell-based treatments, indicating a shift towards more complex and effective treatment strategies.

Declining or Waning

While the journal continues to thrive in many areas, certain themes have seen a decline in focus over recent years. These waning scopes suggest shifts in research priorities or changes in the oncology landscape.
  1. Traditional Chemotherapy Studies:
    Research focusing exclusively on traditional chemotherapy regimens has decreased, as the field shifts towards exploring more targeted and personalized treatment options.
  2. Single-Agent Studies:
    There has been a noticeable decline in studies evaluating single-agent therapies, with a growing preference for combination therapies that leverage multiple mechanisms of action.
  3. Basic Science Research without Clinical Application:
    Papers purely focused on basic science in oncology, without direct clinical implications or applications, appear to be less favored, reflecting a trend towards translational research.

Similar Journals

ONCOLOGY

Elevating the standards of oncology research and practice.
Publisher: KARGERISSN: 0030-2414Frequency: 12 issues/year

ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.

CANCER GENE THERAPY

Shaping the Future of Cancer Research and Therapy
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Gastric Cancer

Shaping the Future of Gastric Cancer Care.
Publisher: SPRINGERISSN: 1436-3291Frequency: 4 issues/year

Gastric Cancer is a leading journal in the field of oncology, published by SPRINGER in Japan. With an ISSN of 1436-3291 and an E-ISSN of 1436-3305, this esteemed journal aims to disseminate high-quality research focused on all aspects of gastric cancer, including its pathophysiology, diagnosis, treatment, and prevention. As an indicator of its academic excellence, Gastric Cancer is ranked in the top quartile (Q1) for Cancer Research, Gastroenterology, Medicine (miscellaneous), and Oncology categories as of 2023. The journal holds impressive Scopus rankings, being positioned #9 in Gastroenterology and #34 in Oncology, demonstrating its critical role in shaping advancements within these disciplines. Although not an open-access publication, it provides various access options for institutions and individuals looking to elevate their understanding of gastric cancer. With a converged publication history from 2000 to 2024, it serves as a vital resource for researchers, professionals, and students dedicated to eradicating this formidable disease.

Translational Oncology

Innovating Tomorrow's Cancer Therapies Today
Publisher: ELSEVIER SCIENCE INCISSN: 1936-5233Frequency: 6 issues/year

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

Cancer Reports

Championing innovation in oncology research.
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

Clinical Lung Cancer

Leading the way in comprehensive lung cancer exploration.
Publisher: CIG MEDIA GROUP, LPISSN: 1525-7304Frequency: 6 issues/year

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

Gynecologic Oncology

Transforming Knowledge into Practice in Gynecologic Oncology
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCEISSN: 0090-8258Frequency: 12 issues/year

Gynecologic Oncology, an esteemed journal published by Academic Press Inc Elsevier Science, stands at the forefront of research in the domains of Obstetrics and Gynecology and Oncology. With an exceptional track record dating from 1972 to 2024, this journal has established itself as a vital resource for scholars and practitioners alike, boasting a remarkable Q1 ranking in both fields as of 2023. Gynecologic Oncology not only ranks #13 out of 209 in Obstetrics and Gynecology and #72 out of 404 in Oncology but also operates within the top percentiles of academic influence, with a 94th percentile in Obstetrics and Gynecology and an 82nd percentile in Oncology on Scopus. Although the journal does not currently offer open access, it remains crucial for disseminating original research, reviews, and advances in the management and treatment of gynecological cancers. Researchers and health professionals will find this journal indispensable for staying informed on the latest advancements and breakthroughs in this vital area of medicine, fostering a deeper understanding and potentially transforming patient care practices.

Onkologie

Illuminating the Complex Landscape of Hematology and Oncology.
Publisher: SPRINGER HEIDELBERGISSN: 2731-7226Frequency: 12 issues/year

Onkologie is a peer-reviewed academic journal published by SPRINGER HEIDELBERG, focusing on the evolving fields of Oncology and Hematology. Established as a significant platform for the dissemination of research in these crucial areas of medicine, Onkologie aims to provide insights into the latest advancements, therapeutic strategies, and clinical practices that shape patient care in oncology and hematology. Despite its current placement in the Q4 category for both disciplines, this journal aspires to foster scholarly dialogues and enhance its contributions to the scientific community. The journal is based in Germany and encourages submissions that promote a deeper understanding of oncology's complex landscape, ensuring that researchers, clinicians, and students have access to a wealth of knowledge essential for clinical practice and further research. With an ISSN of 2731-7226 and E-ISSN of 2731-7234, Onkologie is committed to maintain high standards in publication and peer review, driving innovation and discovery in the fields it represents.

CANCER

Unveiling breakthroughs in oncology since 1948.
Publisher: WILEYISSN: 0008-543XFrequency: 24 issues/year

CANCER, published by Wiley, stands as a pivotal journal in the field of oncology and cancer research, boasting an impressive impact factor and consistently dynamic growth since its inception in 1948. With an ISSN of 0008-543X and an E-ISSN of 1097-0142, this esteemed journal is recognized for its rigorous peer-reviewed articles, making significant contributions to the understanding of cancer biology, treatment modalities, and clinical practices. CANCER holds a distinguished position in the academic community, securing its placement in the Q1 category for both cancer research and oncology, and ranks within the top percentiles on Scopus, indicating its high impact and relevance. The journal is particularly beneficial for researchers, professionals, and students seeking to stay abreast of the latest advancements in cancer science. By addressing essential research questions and providing pathways for new therapies, CANCER continues to play a crucial role in shaping the future of oncology and improving patient outcomes.

International Journal of Clinical Oncology

Shaping the Future of Cancer Management
Publisher: SPRINGER JAPAN KKISSN: 1341-9625Frequency: 6 issues/year

International Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.